Sangamo Therapeutics. has filed a patent for zinc finger fusion proteins that target alpha-synuclein gene to treat neurodegenerative diseases like Parkinson’s and Alzheimer’s. The fusion protein includes a zinc finger protein domain and a transcription repressor domain. GlobalData’s report on Sangamo Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Sangamo Therapeutics, Zinc-finger nucleases was a key innovation area identified from patents. Sangamo Therapeutics's grant share as of January 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.
Zinc finger fusion protein to treat neurodegenerative diseases
See Also:
A fusion protein patent application (Publication Number: US20240018203A1) describes a fusion protein comprising a zinc finger protein (ZFP) domain and a transcription repressor domain. The ZFP domain binds to a specific target region of the human alpha-synuclein gene (SNCA gene), with the fusion protein capable of repressing SNCA gene expression by varying degrees, ranging from 40% to 99%, while minimizing off-target binding or activity. The fusion protein includes six zinc fingers in the ZFP domain and a KRAB domain amino acid sequence from human KOX1 in the transcription repressor domain. The patent also covers a nucleic acid construct containing the fusion protein coding sequence linked to a transcription regulatory element, a recombinant virus incorporating this construct, and a pharmaceutical composition with the recombinant virus and a carrier.
Furthermore, the patent application outlines methods for inhibiting alpha-synuclein expression in human brain cells, particularly neurons, glial cells, ependymal cells, or neuroepithelial cells, which could be beneficial for patients with synucleinopathies like Parkinson's disease, Lewy body dementia, Alzheimer's disease, or multiple system atrophy. The methods involve introducing the fusion protein into the cells directly or via a recombinant virus, such as an adeno-associated virus (AAV) of serotype 9. Additionally, the patent application covers a treatment method for synucleinopathies in patients by administering a recombinant AAV encoding the fusion protein through various injection methods, including intravenous, intrathecal, or intracerebroventricular routes, targeting specific brain regions affected by the disease.
To know more about GlobalData’s detailed insights on Sangamo Therapeutics, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
